Bayer Paid $63 Billion for Monsanto. Today the Whole Company Is Worth Less Than That.

On June 7, 2018, Bayer wired the money and took ownership of Monsanto, paying $128 a share for a total enterprise value of about $63 billion once Monsanto's debt was rolled in.¹ It was the boldest move in the 155-year history of the company that invented aspirin. Here is the number that tells you how it went: by mid-2026, the entire Bayer group — pharma, crop science, consumer health, the whole thing — was worth roughly $44 billion on the market.⁷ Bayer had paid more for one business than the entire company would later be worth. That is not a setback. That is value destruction on a scale that rewrites the textbook.

The story everyone tells is that Bayer was unlucky: it bought a great agriculture company and then a wave of Roundup cancer lawsuits arrived out of nowhere and sank it. Almost every part of that is misleading. The lawsuits were a known risk. The agriculture business was already under pressure. And the financial structure was fragile before a single jury was empaneled. The litigation didn't cause the disaster. It detonated a charge that Bayer's own deal had already planted.

The thesis is simple, and it is not the popular one: Bayer's Monsanto deal was not a black-swan accident but a compounding strategic miscalculation — a 44% premium for a declining asset, financed with debt that starved the rest of the company, with a litigation tail that advisers had flagged and management chose to discount.

The premium that bought a problem

Start with the price, because the price is where the error lived. Bayer's first written proposal, in May 2016, was $122 a share. Monsanto's board rejected it, and Bayer kept raising until it reached $128 in the definitive agreement signed that September — a 44% premium over Monsanto's undisturbed share price.²³ A 44% premium is the market's way of saying you are paying for a future the seller doesn't believe in. To justify it, Monsanto's crop business had to grow and the promised synergies had to land. Neither held. The core of Monsanto's revenue was glyphosate — the active ingredient in Roundup — a commodity herbicide whose pricing power was eroding as generics flooded in. Bayer paid a control premium for an asset whose best years were arguably behind it, and then promised investors the difference would be made up in efficiency.

Those promises — accretion in year one, around $1.5 billion in annual synergies by year three — were the load-bearing beams of the whole rationale.² When they failed to land, there was nothing underneath the premium but debt and hope.

How an all-cash deal quietly mortgaged the future

The structure made everything worse. This was an all-cash transaction, which meant Bayer had to raise tens of billions in financing rather than hand Monsanto shareholders stock and share the risk. To clear regulators, it also had to sell off businesses generating €2.2 billion in annual sales to BASF for about €7.6 billion — surrendering revenue precisely to win permission to take on more debt.⁴ The result was a company carrying an enormous loan against an asset that was supposed to throw off cash and instead began throwing off lawsuits. Every euro servicing that debt was a euro not spent on Bayer's pharmaceutical pipeline — the side of the business with the real growth and the real margins — at exactly the moment its blockbuster drugs were aging toward their patent cliffs. The crop deal didn't just risk the crop division. It quietly rationed capital across the entire firm.

The lawsuits that were never a surprise

And then the bill for the litigation arrived — not as a one-time hit but as an open-ended liability that keeps growing. Bayer has paid out over $11 billion in earlier settlements, and the matter is still not closed. In February 2026 it announced a further $7.25 billion class settlement to resolve current and future non-Hodgkin lymphoma claims — and that deal had only preliminary court approval as of March 2026, not final sign-off.⁵ You can read the strain in Bayer's own books: glyphosate litigation provisions that stood at €6.5 billion in late 2025 jumped to €9.6 billion with the new settlement, lifting total litigation provisions to €11.8 billion, with roughly €5 billion in payouts expected in 2026 alone.⁶ This is the tell. A truly unforeseeable risk gets priced once and absorbed. A foreseeable one keeps reopening, because the buyer never set aside enough to close it. Bayer is still discovering the size of a problem it inherited eight years ago.

Goodwill impairment is the most honest line in any acquisition gone wrong, because it is the company conceding in writing that it overpaid. By the third quarter of 2024, Bayer had amortized or written down €12.9 billion of Crop Science goodwill since the Monsanto deal — including a €3.6 billion write-down in Q3 2023 and a further €3.3 billion in Q3 2024.⁸ Popular coverage tends to seize on one quarter's headline number. The accumulated figure is the real story: nearly €13 billion of the purchase price marked down as never having existed.

Wasn't this just bad luck with American juries?

The honest objection is that the litigation outcome really was surprising — that American product-liability verdicts are notoriously unpredictable, that regulators in many countries still hold glyphosate is safe to use, and that Bayer to this day maintains the chemical does not cause cancer.⁵ All true. No model would have nailed the exact jury awards. But that is the wrong test. The question for due diligence was never 'will we win every case?' It was 'can the deal survive a plausible bad litigation scenario at this price and this debt load?' And the answer, visible at signing, was no. The premium left no margin for error; the all-cash structure left no shock absorber; the synergy case had to perform flawlessly just to break even. The litigation didn't have to be a surprise to be fatal — it only had to be possible. A deal that can only work if everything goes right is not a bold bet. It is a fragile one wearing a bold bet's clothes.

There is a clean way to see the whole thing. Bayer set out to buy the world's leading agriculture company and instead bought the most expensive lesson in modern M&A: that the premium you pay is the safety margin you give away. The lawsuits get the headlines, but they were the spark, not the fuel. The fuel was a price that assumed nothing would go wrong, financed by debt that ensured everything else would. Bayer paid $63 billion to own Monsanto outright — and then watched the market decide the combined company was worth less than that one purchase alone.⁷ The deal didn't out-run its risks. It out-ran its judgment, and it has spent eight years discovering what that costs.